Compile Data Set for Download or QSAR
Report error Found 678 Enz. Inhib. hit(s) with Target = 'Anoctamin-1'
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509719(US20200361871A1, Example 35.24 | US11364246, Examp...)
Affinity DataEC50:  10nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509689(US20200361871A1, Example 31.2 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  10nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509719(US20200361871A1, Example 35.24 | US11364246, Examp...)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509772(US20200361871A1, Example 92.1 | US11364246, Exampl...)
Affinity DataEC50:  10nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509689(US20200361871A1, Example 31.2 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509773(US20200361871A1, Example 92.2)
Affinity DataEC50:  10nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509778(US20200361871A1, Example 93.5 | US11364246, Exampl...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509778(US20200361871A1, Example 93.5 | US11364246, Exampl...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509722(US20200361871A1, Example 36 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509756(US20200361871A1, Example 78 | 4-[[2-(4-Chloro-2-hy...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509722(US20200361871A1, Example 36 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509692(US20200361871A1, Example 31.4 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509758(US20200361871A1, Example 78.2 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  20nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509692(US20200361871A1, Example 31.4 | 4-[[2-(5-Chloro-2-...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509756(US20200361871A1, Example 78 | 4-[[2-(4-Chloro-2-hy...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509758(US20200361871A1, Example 78.2 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  20nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50503445(CHEMBL4445544 | US11274074, Example 1 [Chemical Fo...)
Affinity DataIC50: 21nMAssay Description:Inhibition of YFP-fused ANO1 (unknown origin) expressed in FRT cells after 20 mins by fluorescence quenching methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50503445(CHEMBL4445544 | US11274074, Example 1 [Chemical Fo...)
Affinity DataIC50: 21nMAssay Description:The method for inhibiting the expression of ANO1 (TMEM16A) of the present disclosure includes a step of inhibiting the expression of ANO1 (TMEM16A) i...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/4/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50503445(CHEMBL4445544 | US11274074, Example 1 [Chemical Fo...)
Affinity DataIC50: 22nMAssay Description:Inhibition of ANO1 (unknown origin) expressed in FRT cells assessed as reduction in ATP-induced chloride current after 20 mins by electrophysiologica...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/18/2021
Entry Details Article
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50594075(CHEMBL5186789)
Affinity DataIC50: 24nMAssay Description:Inhibition of YFP tagged ANO1 (unknown origin) expressed in FRT cells incubated for 24 hrs by fluorescence plate reader assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM11242(5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxybenza...)
Affinity DataIC50: 28nMAssay Description:Inhibition of YFP tagged ANO1 (unknown origin) expressed in FRT cells incubated for 24 hrs by fluorescence plate reader assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50594073(CHEMBL5206041)
Affinity DataIC50: 29nMAssay Description:Inhibition of YFP tagged ANO1 (unknown origin) expressed in FRT cells incubated for 24 hrs by fluorescence plate reader assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetAnoctamin-1(Mouse)
Korea University

Curated by ChEMBL
LigandPNGBDBM50239465(CHEMBL4080525 | US11274074, Control [Ani9])
Affinity DataIC50: 30nMAssay Description:Inhibition of GFP-fused mouse ANO1 channel expressed in HEK293A cells assessed as inhibition of ATP-induced channel current amplitude at membrane pot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50239459(CHEMBL4074929)
Affinity DataIC50: 30nMAssay Description:Inhibition of YFP tagged ANO1 (unknown origin) expressed in FRT cells incubated for 24 hrs by fluorescence plate reader assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2023
Entry Details
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50239459(CHEMBL4074929)
Affinity DataIC50: 30nMAssay Description:Inhibition of ANO1 channel (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50239459(CHEMBL4074929)
Affinity DataIC50: 30nMAssay Description:Inhibition of human TMEM16A expressed in FRT cells assessed as reduction of ATP-induced in chloride conductance preincubated for 5 mins followed by A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/22/2019
Entry Details Article
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509763(US20200361871A1, Example 81.4 | N-(4-Fluoro-1-bicy...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509775(US20200361871A1, Example 93.2 | US11364246, Exampl...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509762(US20200361871A1, Example 81.3 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509762(US20200361871A1, Example 81.3 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509763(US20200361871A1, Example 81.4 | N-(4-Fluoro-1-bicy...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509594(US20200361871A1, Example 3.14b | US11364246, Examp...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509594(US20200361871A1, Example 3.14b | US11364246, Examp...)
Affinity DataEC50:  40nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509775(US20200361871A1, Example 93.2 | US11364246, Exampl...)
Affinity DataEC50:  40nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509730(US20200361871A1, Example 44 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Mouse)
Korea University

Curated by ChEMBL
LigandPNGBDBM50239459(CHEMBL4074929)
Affinity DataIC50: 50nMAssay Description:Inhibition of GFP-fused mouse ANO1 channel expressed in HEK293A cells assessed as inhibition of ATP-induced channel current amplitude at membrane pot...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509649(US20200361871A1, Example 7.15 | US11364246, Exampl...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509730(US20200361871A1, Example 44 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509757(US20200361871A1, Example 78.1 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509724(US20200361871A1, Example 38 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509774(US20200361871A1, Example 93.1 | US11364246, Exampl...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509724(US20200361871A1, Example 38 | 4-[[2-(5-Chloro-2-hy...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509757(US20200361871A1, Example 78.1 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509649(US20200361871A1, Example 7.15 | US11364246, Exampl...)
Affinity DataEC50:  50nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509774(US20200361871A1, Example 93.1 | US11364246, Exampl...)
Affinity DataEC50:  50nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509776(US20200361871A1, Example 93.3 | US11364246, Exampl...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509226(US20200361871A1, Example 1.6 | 4-[[2-(5-Chloro-2-h...)
Affinity DataEC50:  60nMAssay Description:Compound activity was quantified by measuring the increase in current upon compound addition and expressing this as a percentage increase of baseline...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/13/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509725(US20200361871A1, Example 39 | N-(4-tert-Butylcyclo...)
Affinity DataEC50:  60nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM50239465(CHEMBL4080525 | US11274074, Control [Ani9])
Affinity DataIC50: 60nMAssay Description:Inhibition of human ANO1 channel expressed in HEK293 cells incubated for 10 mins by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/26/2022
Entry Details Article
PubMed
TargetAnoctamin-1(Human)
Tmem16A

US Patent
LigandPNGBDBM509630(US20200361871A1, Example 5.36 | N-(1,1-Dimethylpro...)
Affinity DataEC50:  60nMAssay Description:Cell Culture and PreparationFisher rat thyroid (FRT) cells stably expressing human TMEM16A (TMEM16Aabc variant; Dr Luis Galietta, Insituto Giannina, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

Displayed 1 to 50 (of 678 total ) | Next | Last >>
Jump to: